Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

FEMY vs BLFS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BLFS Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 9–1 Matrix Metrics)

BLFS Overall Winner 6-Pillar Tally: FEMY 0 – 6 BLFS Matrix Metrics: FEMY 1 – 9 BLFS

As of Nov 16, 2026, BioLife Solutions Inc. (BLFS) is the stronger overall head-to-head candidate over Femasys Inc. (FEMY) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). FEMY carries a Unified Composite Score of 52.6/100 (HOLD) at $1.28 (N/M Forward P/E, -763.9% operating margin), whereas BLFS carries 46.0/100 (HOLD) at $38.61 (117.0x Forward P/E, 6.0% operating margin).

  • Composite vs. Pillar Nuance: While FEMY currently prints a higher short-term Unified Composite Score (52.6/100 HOLD vs. BLFS 46.0/100 HOLD), BLFS captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (6.0% vs. -763.9% operating margin) and revenue trajectory (+21.5% vs. -18.9% YoY).
  • Technical & Structure Timing Caution: FEMY is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.6); meanwhile BLFS trades in a Markup technical trend (BREAKOUT options phase, RSI 60.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About FEMY vs BLFS
FEMY NASDAQ
Femasys Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$1.28
-9.86% 1D
Market Cap $11.9M
TTM Revenue $2.3M
Forward P/E N/M
Beta / 30D Vol 4.01β · 72% Vol
Unified Composite Score
52.6 / 100 HOLD
Tech 61.0 Fund 62.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -21.5%), weak momentum, RSI 35
RSI-14: 34.6 · SMA20: $1.43 · SMA50: $1.92
BLFS NASDAQ Head-to-Head Winner
BioLife Solutions Inc.
Electromedical & Electrotherapeutic Apparatus
$38.61
+3.51% 1D
Market Cap $1.8B
TTM Revenue $107M
Forward P/E 117.0x
Beta / 30D Vol 1.05β · 31% Vol
Unified Composite Score
46.0 / 100 HOLD
Tech 27.0 Fund 46.0 Flow 59.0 Mom 56.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (10.2% over 20 days), RSI 61
RSI-14: 60.5 · SMA20: $37.08 · SMA50: $35.70

6-Pillar Scorecard Institutional Category Breakdown (FEMY 0 – 6 BLFS)

Columns: Metric · FEMY · BLFS
1. Valuation Multiples BLFS
Forward P/E N/M 117.0x
Trailing P/E N/M 37.3x
PEG Ratio N/M N/M
EV / Revenue 4.9x 17.0x
2. Growth & Scale BLFS
Revenue Growth (YoY) -18.9% +21.5%
Earnings Growth (YoY) +0.0% -13.9%
TTM Revenue (USD) $2.3M $107M
Market Cap $11.9M $1.8B
3. Profitability & Quality BLFS
Gross Margin 60.9% 63.6%
Operating Margin -763.9% 6.0%
Net Profit Margin 0.0% 54.4%
Return on Equity (ROE) -425.0% 12.8%
4. Balance Sheet & Cash Flow BLFS
Cash Generation (TTM) -$19M -$2.2M
Cash Flow Margin N/A -2.1%
Net Cash / Leverage -$658,045 Net Debt (0.65x D/E) $8.3M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BLFS
Options Structure Phase UNCLASSIFIED BREAKOUT
Current IV / %ile N/A (N/A) 40.1% (6th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Markup
6. R&D & Supply-Chain Moat BLFS
OpEx & R&D Intensity N/A 57.6% of Rev ($61M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Instruments & Supplies Operator Medical Instruments & Supplies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: FEMY (1) vs BLFS (9)
Institutional Metric FEMY BLFS Criterion Row Edge
Market Capitalization
Scale
$11.9M $1.8B Larger Scale BLFS
Trailing P/E Ratio
Valuation
N/M 37.3x Lower Multiple BLFS
Forward P/E Ratio
Valuation
N/M 117.0x Lower Multiple BLFS
Revenue Growth (YoY)
Growth
-18.9% +21.5% Higher Growth BLFS
Operating Margin (TTM)
Profitability
-763.9% 6.0% Higher Margin BLFS
Net Profit Margin
Profitability
0.0% 54.4% Higher Margin BLFS
Return on Equity (ROE)
Capital Efficiency
-425.0% 12.8% Higher ROE BLFS
52-Week Range Position
Momentum
17% ($0–$6) 95% ($18–$40) Stronger Trend BLFS
Beta / 30D Volatility
Risk Regime
4.01β · 72% Vol 1.05β · 31% Vol Lower Realized Risk BLFS
Unified Institutional Score
Composite Signal
52.6 / 100 (HOLD) 46.0 / 100 (HOLD) Higher Composite FEMY
Trailing 12M Revenue (USD)
Operating Scale
$2.3M $107M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
60.9% 63.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 4.9x EV/Rev N/M PEG · 17.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$19M (-$658,045 Net Debt (0.65x D/E)) -$2.2M ($8.3M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BLFS +42.66 pp
FEMY: -33.99% · BLFS: +8.67%
3M Horizon BLFS +86.04 pp
FEMY: -47.8% · BLFS: +38.24%
6M Horizon FEMY +269.74 pp
FEMY: +370.1% · BLFS: +100.36%
1Y Horizon FEMY +90.68 pp
FEMY: +144.26% · BLFS: +53.58%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period FEMY Revenue BLFS Revenue FEMY Op. Margin BLFS Op. Margin Margin Leader
FY2018 N/A $20M N/A 18.5% BLFS
FY2019 N/A $30M N/A -0.8% BLFS
FY2020 $0M $50M -668.0% -13.0% BLFS
FY2021 $0M $120M -706.7% -29.5% BLFS
FY2022 $0M $80M -961.7% -7.8% BLFS
FY2023 $0M $70M -1353.4% -25.3% BLFS
FY2024 $0M $70M -1091.8% -6.0% BLFS
FY2025 $0M $100M -767.0% -17.3% BLFS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
FEMY UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact FEMY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BLFS BREAKOUT
38d in phase · OBV ACCUMULATION
Current IV 40.1%
IV Percentile 6th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact BLFS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
FEMY Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $11.9M market capitalization and -763.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BLFS Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $1.8B market capitalization and 6.0% operating margin.
OpEx & R&D Reinvestment 57.6% of Rev ($61M)
90D Engineering Disclosures 0 Published

Investor FAQ FEMY vs BLFS Key Questions & Quantitative Answers

As of Nov 16, 2026, BioLife Solutions Inc. (BLFS) is the stronger overall head-to-head candidate over Femasys Inc. (FEMY) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). FEMY carries a Unified Composite Score of 52.6/100 (HOLD) at $1.28 (N/M Forward P/E, -763.9% operating margin), whereas BLFS carries 46.0/100 (HOLD) at $38.61 (117.0x Forward P/E, 6.0% operating margin). Composite vs. Pillar Nuance: While FEMY currently prints a higher short-term Unified Composite Score (52.6/100 HOLD vs. BLFS 46.0/100 HOLD), BLFS captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (6.0% vs. -763.9% operating margin) and revenue trajectory (+21.5% vs. -18.9% YoY). Technical & Structure Timing Caution: FEMY is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.6); meanwhile BLFS trades in a Markup technical trend (BREAKOUT options phase, RSI 60.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BLFS leads the Growth & Scale pillar: FEMY posts -18.9% YoY revenue growth and +0.0% YoY earnings growth on $2.3M TTM revenue (60.9% gross margin, -763.9% operating margin), compared with BLFS at +21.5% YoY revenue growth and -13.9% YoY earnings growth on $107M TTM revenue (63.6% gross margin, 6.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), FEMY cumulative revenue shifted N/A while BLFS shifted +400.0%. In operating R&D and SG&A reinvestment, FEMY deploys N/A (0 90-day corporate R&D disclosures) versus 57.6% of Rev ($61M) (0 disclosures) for BLFS.

BLFS screens cheaper on headline valuation multiples. FEMY trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 4.9x EV/Revenue (unreported FCF margin), whereas BLFS trades at 117.0x Forward P/E, 37.3x Trailing P/E, N/M PEG, and 17.0x EV/Revenue (-2.1% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FEMY (-425.0% ROE) versus BLFS (12.8% ROE) capital efficiency.

In options market volatility and institutional positioning, FEMY carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.01β · 72% Vol realized risk). By comparison, BLFS carries 40.1% implied volatility (6th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.05β · 31% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.